A service of arranging or bringing about contact between an investment manager and an issuer or potential issuer.
Gerard Michel Brings the Experience Needed to Lead Delcath as it Transitions from a Development to Commercial Stage CompanyJohn Purpura Appointed Chief Operating Officer with Operational, Manufacturing and Regulatory Responsibilities NEW YORK, Oct. 01, 2020 -- Delcath...
NEW YORK, Sept. 10, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will participate in two upcoming virtual investor conferences:...
NEW YORK, Aug. 25, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced management will present at the LD Micro 500 Virtual Conference Tuesday,...
NEW YORK, Aug. 13, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, announces financial results for the quarter ended June 30, 2020, and will host an earnings...
NEW YORK, Aug. 06, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that it will host a conference call on August 13, 2020 at 4:30 PM Eastern...
NEW YORK, Aug. 03, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on liver-directed treatment of rare primary and metastatic cancers, today announced that John Purpura, interim Chief Executive Officer, will be presenting...
Appoints John Purpura as interim Chief Executive Officer.Reiterates intention to announce top-line data from Phase 3 FOCUS trial by year-endAccelerates shift to commercialization planning NEW YORK, May 26, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an...
Highlights include $22 million public offering, uplisting to Nasdaq, Pivotal Registration Trial enrollment completed, and Pivotal Registration Topline Data Expected in 2020 NEW YORK, May 15, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology...
NEW YORK, May 05, 2020 -- Delcath Systems, Inc. (NASDAQ: DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the closing of its previously announced underwritten public offering of 2.2...
NEW YORK, May 01, 2020 -- Delcath Systems, Inc. (OTCQB:DCTH NASDAQ:DCTH), an interventional oncology company focused on the treatment of rare primary and metastatic cancers of the liver, today announced the pricing of a $22 million underwritten public offering of 2.2...